Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    

SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

Allergan, Inc. : Allergan 3rd-Quarter Profit Edges Down; Weighs Options for Obesity Segment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2012 | 03:07pm CEST
   By Tess Stynes 
 

Allergan Inc.'s (AGN) third-quarter earnings edged down slightly as the maker of Botox and medical devices posted more one-time items, masking continued sales growth for top drug Botox.

Since the end of the quarter, Allergan said it is exploring strategic options for its obesity intervention business, including among other things, a potential sale of the unit.

For the year, the company raised the lower end of its guidance and now expects per-share earnings of $4.17 and $4.19 on product sales of $5.7 billion to $5.8 billion. Its prior view was for per-share profit of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion.

For the current quarter, Allergan forecast per-share earnings of $1.18 to $1.20 on revenue of $1.47 billion to $1.55 billion. Analysts polled by Thomson Reuters most recently expected $1.20 and $1.51 billion, respectively.

Chief Executive David E.I. Pyott in August had commented that the company is watching carefully for signs of economic vulnerability, but doesn't see a threat to long-term goals. Allergan's cosmetic medical products seem to appeal to people with greater economic means and purchasing power, providing some shelter from economic turmoil, he said at the time.

Allergan reported a profit of $249.4 million, down from $249.8 million a year earlier. On a per-share basis, earnings were up at 82 cents from 81 cents amid fewer shares outstanding. Excluding acquisition and restructuring related charges and other items, earnings were up at $1.06 from 92 cents.

Revenue increased 6.4% to $1.41 billion. Product net sales were up 6.1% to $1.39 billion, and were up 9.4% excluding currency impacts.

The company in August forecast per-share earnings of $1.02 to $1.04 on revenue of $1.37 billion to $1.45 billion.

Gross margin rose to 86.7% from 85.8% amid the increased revenue.

Sales of Botox, which is used as a medical treatment and wrinkle-fighting cosmetic tool, rose 8.8% to $431.6 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue-increased 8.1%, or roughly 11% excluding currency fluctuations.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
06/07 Mylan defends chairman to ISS ahead of June 22 investor vote
06/07 ALLERGAN : to Present New Data on Chronic Migraine at the American Headache Soci..
06/05 FEATURED COMPANY NEWS - MYLAN LAUNCH : Generic Reclast® Injection and Generic Az..
05/31 ALLERGAN : to Present Data from its Anti-Infectives Portfolio at ASM Microbe 201..
05/26 ALLERGAN PLC : Entry into a Material Definitive Agreement, Other Events, Financi..
05/25 ALLERGAN PLC : Other Events, Financial Statements and Exhibits (form 8-K)
05/24 ALLERGAN : Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch R..
05/23 ALLERGAN PLC : Other Events, Financial Statements and Exhibits (form 8-K)
05/18 HEALTH CANADA APPROVES ALLERGAN PLC : AGN) IBS Drug Viberzi
05/16 ALLERGAN : Eyepowerment™ Campaign Releases Survey Revealing the Importance..
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chief Executive Officer
Maria Teresa Hilado Chief Financial Officer
Raymond H. Diradoorian Executive VP-Global Technical Operations
Joann Bradley Investor Relations Contact
David Nakasone Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.0
JOHNSON & JOHNSON18.42%367 520
NOVARTIS13.09%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results